Figure 1. Cohort Development in an Analysis of Longer-term Follow-up of Critically Ill Participants in the REMAP-CAP COVID-19 Clinical Trial.

^aAn additional 910 non–critically ill patients were enrolled in domains.

^bAdditional 42 patients with unknown vital status at 90 d were from sites not participating in 180-d follow-up.

^cQuality of life on the EQ-5D-5L; scores from −0.593 to 1.00 (full health).

^dSelf-reported present health state, ranging from 0 (worst) to 100 (best).

^eCovers 6 domains of functioning; 0 (no difficulty) to 4 (extreme difficulty).